Remi Barbier is the CEO of Cassava Sciences, Inc., a company focused on developing treatments for neurodegenerative diseases. He holds a Bachelor of Arts from Pennsylvania State University and has been in the role since July 1998. Under his leadership,...

Remi Barbier is the CEO of Cassava Sciences, Inc., a company focused on developing treatments for neurodegenerative diseases. He holds a Bachelor of Arts from Pennsylvania State University and has been in the role since July 1998. Under his leadership, Cassava has made significant strides, including several high-profile partnerships and clinical advancements. In 2023, Remi's total compensation reached over $1.22 million, mainly through his salary of $1.215 million, highlighting his financial commitment to the firm. In 2024, he announced his resignation effective September 2024, which is deemed ‘Other Than for Cause’, allowing him to collect a generous severance of $1.23 million. Interestingly, from late 2019 to 2021, Remi saw a peak in insider trading activity, with his highest transaction being around $85.3 million in July 2021. This reflects his significant stake in the company and how he strategically capitalized on those holdings. Remi's departure marks a new chapter for Cassava as it seeks to continue its mission without him in the lead.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Cassava Sciences CEOs

C

Remi Barbier

Founder and Ex-CEO of Cassava Sciences

Education

Bachelor of Arts from Pennsylvania State University

Field of Expertise

Finance & Banking - Finance

Sector of Economy

Healthcare

Born

January 1, 1959 - 66 years ago

CEO of Cassava Sciences for

26 years 2 months (Jul 1998 - Sep 2024)

Previous Experience

President and CEO of Cassava Sciences, Inc. since its founding in 1998, with extensive experience in investment management and corporate leadership.

Rivals

Competitors/colleagues of Remi Barbier

Holdings

See how much did Remi Barbier make over time.

Remi Barbier has been actively managing a significant stake in Cassava Sciences, which has shown notable fluctuations over the years. In December 2019, his holdings were valued at approximately $9.09 million. By early 2021, that value skyrocketed to an impressive...

Remi Barbier has been actively managing a significant stake in Cassava Sciences, which has shown notable fluctuations over the years. In December 2019, his holdings were valued at approximately $9.09 million. By early 2021, that value skyrocketed to an impressive $57.02 million in February and an astonishing $85.30 million in July, showcasing strategic moves that benefitted his personal wealth. His highest holdings were seen during 2021, coinciding with critical developments in the company. His ownership has decreased slightly since then, with 2023 showing consistent values around the $30 million mark. As of 2024, the trend suggests that he still holds substantial wealth connected to Cassava,"

Insider Trading

See recent insider trades of Remi Barbier.

SAVA

$95.90K

SAVA at $9.59/share

Sep 24, 2020

Purchase

SAVA

$553.00K

SAVA at $5.53/share

Dec 31, 2019

Purchase

SAVA

$41.50K

SAVA at $4.15/share

Dec 26, 2019

Purchase

SAVA

$4.29K

SAVA at $1.65/share

Dec 18, 2019

Purchase

SAVA

$4.29K

SAVA at $1.65/share

Dec 18, 2019

Purchase

Compensation History

See how much did Remi Barbier make over time.

In 2023, Remi Barbier earned a total compensation of approximately $1.22 million, primarily stemming from his salary of $1.215 million. He did not receive any bonuses or stock awards that year, indicating an unusual alignment of risk and reward linked to Cassava’s performance metrics. Over the years, his compensation has fluctuated based on various performance metrics set by the board. His pay has been consistently tied to achieving clinical and corporate goals, with previous years also showing considerable earnings, such as $1.89 million in 2017. This emphasis on aligning pay with performance illustrates Cassava’s strategy in retaining top talent while driving company growth. Remi is also set to receive a severance package of $1.23 million after his resignation in late 2024, reflecting his significant service and impact on the company.

Year

2023

Total Compensation

$1.22M

Salary

$1.22M

Board Justification

The compensation program is designed to attract and retain high-performing executive talent, align compensation with performance, and ensure competitiveness with industry standards.

Bonus

$0.00

Board Justification

No bonuses were awarded to the Company's executive officers for 2023.

Other

$9.39K

Board Justification

Represents life insurance premiums paid by the company on behalf of Mr. Barbier.

Restricted Stock

$0.00(0 N/A)

Board Justification

No stock awards were granted in 2023.

Performance Metrics

The performance metrics for 2023 included corporate performance goals related to clinical program milestones and overall company performance.

Other Cassava Sciences CEOs

Here are other CEOs of Cassava Sciences

Richard J. Barry

CEO of Cassava Sciences

July 2024 - Present